Voyager Therapeutics (NASDAQ:VYGR) CFO Sells $17,598.36 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CFO Nathan Jorgensen sold 4,668 shares of the business’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.77, for a total value of $17,598.36. Following the sale, the chief financial officer owned 151,416 shares of the company’s stock, valued at approximately $570,838.32. This represents a 2.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Voyager Therapeutics Stock Down 3.1%

Shares of NASDAQ:VYGR opened at $4.10 on Friday. The stock has a market capitalization of $227.96 million, a PE ratio of -1.90 and a beta of 1.30. The firm’s 50 day moving average price is $3.86 and its 200-day moving average price is $4.12. Voyager Therapeutics, Inc. has a twelve month low of $2.64 and a twelve month high of $5.55.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Montreal Can bought a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at $36,000. Wexford Capital LP bought a new stake in Voyager Therapeutics during the third quarter valued at about $42,000. ProShare Advisors LLC purchased a new position in shares of Voyager Therapeutics in the fourth quarter valued at about $44,000. CIBC Asset Management Inc purchased a new position in shares of Voyager Therapeutics in the fourth quarter valued at about $45,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Voyager Therapeutics in the second quarter worth about $50,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Wall Street Zen cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, HC Wainwright lowered their target price on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.75.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.